# Fontan Outcomes Network Update

## Gail Wright, M.D.

## Erin Hoffmann Medical Director **Comprehensive Single Ventricle Program Clinical Associate Professor of Pediatrics**



Lucile Packard

Stanford

WSOPC May 5, 2019 Children's Hospital



Disclosures:

No financial conflicts Gratitude for philanthropic support of SVP

I believe in healthcare for all Americans

I believe in building networks not walls

I have learned a lot about living wholeheartedly from people born with half a heart



Lucile Packard Children's Hospital Stanford



## Landscape of Fontan work

- Lots going on!
- US & international collaborations
- Lots of progress AND lots of unknowns
- Lots of "green grass and opportunity" for whole community-> clinicians, patients, and families



## Paradigm Shift in Single V Lifelong Care

### > Thrive not just survive

Optimize functional outcomes, rather than treating once failing physiology has already developed

Anticipatory, longitudinal care for early identification and treatment of morbidity

Multi-center, collaborative research, QI, and advocacy









### Australia New Zealand Fontan Registry

Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Involvement of patients and parents in research undertaken by the Australian and New Zealand 1. Zealand Fontan Registry. 7. Fontan Registry. Wilson TG, d'Udekem Y, Winlaw DS, Cordina RL, Celermaier DS, Wheaton GR, Bullock A, Gentles d'Udekem Y, Forsdick V, du Plessis K. TL, Weintraub RG, Justo RN, Grigg LE, Radford DJ, Hardikar W, Cheung M, Cain TM, Rao P, Cardiol Young. 2018 Apr;28(4):517-521. doi: 10.1017/S1047951117001494. Epub 2017 Aug 17. Alexander SI, Ayer J, Verrall C, Du Plessis K, Chapman J, Rice K, Barry J, Zannino D, Iyengar AJ; PMID: 28814350 Australian and New Zealand Fontan Registry. Similar articles Int J Cardiol. 2018 Jul 25. pii: S0167-5273(18)30069-X. doi: 10.1016/j.ijcard.2018.07.118. [Epub ahead of print] PMID: 30060970 Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure Similar articles 8. Huang L. Schilling C. Dalziel KM, Xie S, Celermajer DS, McNeil JJ, Winlaw D, Hornung TS, Radford DJ, Grigg LE, Bullock A, Wheaton GR, Justo RN, Blake J, Bishop R, Du Plessis K, d'Udekem Y. "Will she live a long happy life?" Parents' concerns for their children with Fontan circulation. Am J Cardiol. 2017 Aug 1;120(3):467-472. doi: 10.1016/j.amjcard.2017.04.049. Epub 2017 May 11. 2. du Plessis K, Peters R, King I, Robertson K, Mackley J, Maree R, Stanley T, Pickford L, Rose B, PMID: 28583678 Orchard M, Stewart H, d'Udekem Y. Similar articles Int J Cardiol Heart Vasc. 2018 Mar 9;18:65-70. doi: 10.1016/j.ijcha.2018.02.008. eCollection 2018 Mar. PMID: 29876506 Free PMC Article Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the Similar articles 9. period through to Fontan completion Huang L, Dalziel KM, Schilling C, Celermajer DS, McNeil JJ, Winlaw D, Gentles T, Radford DJ, "How long will I continue to be normal?" Adults with a Fontan circulation's greatest concerns. Cheung M, Bullock A, Wheaton GR, Justo RN, Selbie LA, Forsdick V, Du Plessis K, d'Udekem Y. 3. du Plessis K, Peters R, King I, Robertson K, Mackley J, Maree R, Stanley T, Pickford L, Rose B, Int J Cardiol. 2017 Aug 1;240:178-182. doi: 10.1016/j.ijcard.2017.04.056. Epub 2017 Apr 20. Orchard M. Stewart H. d'Udekem Y. PMID: 28456482 Int J Cardiol. 2018 Jun 1;260:54-59. doi: 10.1016/j.ijcard.2018.01.098. Similar articles PMID: 29622455 Similar articles Evolution of Left Ventricular Size in Late Survivors of Surgery for Hypoplastic Left Heart Syndrome. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. 10. Bjurborn M, Iyengar AJ, Moenkemeyer F, Konstantinov IE, Brizard CP, d'Udekern Y. 4. Dennis M, Zannino D, du Plessis K, Bullock A, Disney PJS, Radford DJ, Hornung T, Grigg L, Cordina Ann Thorac Surg. 2017 Sep;104(3):926-931. doi: 10.1016/j.athoracsur.2017.01.051. Epub 2017 Apr 12. R, d'Udekem Y, Celermajer DS. PMID: 28410632 Similar articles J Am Coll Cardiol. 2018 Mar 6;71(9):1009-1017. doi: 10.1016/j.jacc.2017.12.054. PMID: 29495980 Similar articles 11. Schilling C, Dalziel K, Iyengar AJ, d'Udekem Y. Life After Surviving Fontan Surgery: A Meta-Analysis of the Incidence and Predictors of Late Death. Heart Lung Circ. 2017 Aug;26(8):e44-e47. doi: 10.1016/j.hlc.2017.02.003. Epub 2017 Mar 6. 5. Poh CL, d'Udekem Y. PMID: 28372885 Heart Lung Circ. 2018 May;27(5):552-559. doi: 10.1016/i.hlc.2017.11.007. Epub 2017 Dec 20. Review. Similar articles PMID: 29402692 Similar articles Common atrioventricular valve failure during single ventricle palliation+. 12. King G, Gentles TL, Winlaw DS, Cordina R, Bullock A, Grigg LE, Alphonso N, Radford DJ, Zannino D, Twenty-Five Year Outcomes of the Lateral Tunnel Fontan Procedure.

-----

6. Wilson TG, Shi WY, Iyengar AJ, Winlaw DS, Cordina RL, Wheaton GR, Bullock A, Gentles TL, Weintraub RG, Justo RN, Grigg LE, Radford DJ, d'Udekem Y: Australia and New Zealand Fontan

The Cost Differential Between Warfarin Versus Aspirin Treatment After a Fontan Procedure.

Buratto E, d'Udekem Y. Eur J Cardiothorac Surg. 2017 Jun 1:51(6):1037-1043. doi: 10.1093/ejcts/ezx025.



# STATE OF THE ART CLINICAL CARE OF THE FONTAN CIRCULATION –

## A MULTI-INSTITUTIONAL SURVEY OF PRACTICE VARIABILITY IN IDENTIFIED FONTAN PROGRAMS ACROSS THE U.S.

DiMaria, M et. al. Pediatric Cardiology 2018





## Surveillance:

- Very little scientific data to tell us:
  - What to check
  - How often
  - What to do when we find a problem
- Need collaboration to redefine quality outcomes

- Younoszai, A., et. al., World Congress of Pediatric Cardiology 2017
- DiMaria, M et. al. Pediatric Cardiology 2018

## **American Heart Association (AHA)**

- Scientific Statement on the Care of the Fontan
- Compendium of current knowledge about Fontan circulation- 20 international expert authors; addresses both child and adult

- Embargo
- "Coming Soon" .....for the past 2 years

### Concept of Surveillance Matrix by domains & age

### Surveillance Matrix: Domains and Ages

	School Entry (4-5 y)	Early School Age (6-8y)	Childhood (9-12y)	Early Teen (13-15 y)	Late Teen (16-18)
Cardiac- Imaging, CPET, rhythm					
Neurodev Hepatic Lymphatic Endo Renal					
Nutrition Care Coordination					
<b>Resiliency</b> <b>Transition</b>					

### • Fontan Udenafil Exercise Longitudinal Trial (FUEL)

- <u>What</u>: A six-month randomized, placebo control trial in adolescents after Fontan
- **Outcomes**: Exercise, ventricular function, vascular function
- <u>Who</u>: 400 subjects at 30 sites in the United States, Canada and South Korea
- <u>Status</u>: Recruitment Complete!

### • FUEL Open Label Extension (FUEL OLE)

- <u>What</u>: A 12-24 month safety trial for new subjects or FUEL participants
- **Outcomes**: Safety, efficacy (exercise, ventricular function, vascular function)
- <u>Who</u>: 300 subjects at 28 sites in the United States and Canada
- <u>Status</u>: Recruitment ongoing


### • FUEL Fontan Associated Liver Disease Ancillary Study (FUEL FALD)

- <u>What</u>: An evaluation of the impact of udenafil on liver stiffness
- **Outcomes**: MR and ultrasound elastography and biomarkers of liver fibrosis
- <u>Who</u>: Up to 100 subjects who are also participating in FUEL OLE
- <u>Status</u>: Recruitment ongoing



## Total of eight grants submitted:

- 1. The Systemic Right Ventricle: Risks and Outcomes of Congestive Heart Failure." Craig Broberg and TGA subgroup, AHA
- 2. Cardiovascular Outcomes of Pregnancy in Turner Syndrome: A Multi-Center Retrospective Case-Control Study. Jasmine Grewal and pregnancy subgroup, University of British Columbia
- 3. The additive effects of inspiratory muscle and skeletal muscle training in the Fontan population, Anitha John, Salil Ginde, Fred Wu, Elisa Bradley and the Fontan subgroup, PHN
- 4. A Multi-Institutional Neurocognitive Discovery Study (MINDS) in ACHD, Scott Cohen, Ali Zaidi and the neurodev. subgroup, PHN
- 5. Predictive Value of Hepatic Fibrosis Scores in Patients with Fontan Circulation. Fred Wu and Fontan subgroup, CHF
- 6. Fontan Outcomes Study To Improve Transplant Experience and Results: The FOSTER Study, Matt Lewis, CHF
- 7. Characterizing Hepatic Fibrosis Scores in Patients with Fontan Circulation. Fred Wu and Fontan subgroup, Saving Tiny Hearts
- 8. Engaging the Fontan population to improve Physical Activity Participation. Anitha John and the Fontan subgroup, PCORI





Stanford MEDICINE



## FONTAN OUTCOMES NETWORK UPDATE

Carole Lannon, Diane Pickles, Jack Rychik, Gail Wright

NPCQIC Spring Learning Session: May 4, 2019

## WHY: THE VISION

- To enable our single ventricle patients to survive but not ensure that they thrive
- To wait for failed physiology and then treat the failure rather than work to prevent the failures
- To accept neurodevelopmental deficits and social emotional problems as part of the disease
- To live with the fear and uncertainty that patients and families currently face each day





## FONTAN OUTCOMES NETWORK



## **Fontan Outcomes Network:**

Our vision: to dramatically improve outcomes for individuals with Fontan physiology

Our mission: to optimize longevity and quality of life for individuals with Fontan physiology and their families by improving their physical health and functioning, neurodevelopment, and emotional health and resilience.

- We will accomplish this through
  - Development of a Learning Health System co-produced with patients, parents, clinicians and researchers
  - Dissemination of "best practices" among clinical sites
  - Discovery of new therapies

### **Quality of Life** Better quality of life for patients, siblings and caregivers

### **Longevity** Longer lives for patients

### Resilience & Emotional Health

- Good quality of life
- Effective & healthy coping strategies
- Good social connections and support
- Minimal/manageable psychological distress

### Neurodevelopment

- Increased life skills and executive functioning
- Advancing to college or career/vocational training and other key milestones
- Increases in adaptive functioning measures

### Physical Health & Functioning

- Increased survival without transplant
- Increased/maintenance of exercise capacity
- Decreased major morbidities


### You only see obstacles when you take your eyes off the goal.

## WHAT: CURRENT APPROACH & STATUS

## **Key Driver Diagram: Fontan Outcomes Network**

### **Global Aim:**

*Optimize longevity & QoL of individuals with Fontan circulation & optimize QOL of their families* 



### **Fontan Outcomes Network**

#### System Drivers System Driver Measures • Increase in % of patients who maintain exercise capacity at 90% of initial maxv02 (usually obtained at 10-12 years Optimize health and of age) wellness of individuals with Increase in % of patients who survive without transplant Fontan circulation by Decrease in % of patients who experience (?1 component) preserving functional status of Major Morbidities Bundle Achieve ongoing developmental surveillance Improved life skills / executive functioning consistent with individual's abilities: including early identification --Increase % of individuals graduating high school and and interventions to support advancing to college or career/vocational training neurodevelopmental needs, -Increase score on standard measure of adaptive so that each individual meets functioning (ABAS-3 selected items) in all domains his / her full potential\* \* full potential = success in family, school, work, and relationships Increase % of individual and family members who good QOL Increase in the % of individuals and family memb report they have effective and healthy coping str **Emotional Health &** Increase in the % of individuals and family mem report good social connections/ support

Increase the % of individuals who report minimal/manageable psychological distress

#### Outcome AIM(s)

#### OOL

Increase quality of life (scored by validated tool) of patients, siblings and caregivers

#### Longevity:

Increase average length of life

**Resilience** of Individuals with Fontan Circulation and their Families

## Fontan Outcomes Network: guided by data

## Registry

- Fontan patients: ALL Ages (across lifespan, not just pediatric)
- Enrollment: at time of Fontan or 1<sup>st</sup> clinic visit after registry live
- Start with consensus-driven, prioritized, core data
- Ongoing collection of key data elements
  - Across key driver domains: Physical health and functioning, resilience and emotional health, neurodevelopment
  - Clinic visits and prompt for annual visit follow up
  - Patient/parent reported outcomes

## Fontan Outcomes Network: "Co-production"

### > Network

- Collaboration among patients, parents, multidisciplinary clinicians, and researchers informs prioritization of outcomes
- Request to data vendor will include incorporation of existing data from other CNU registries
- Sustainable and scalable infrastructure
- Bridging with ACHD, Heart Failure, community cardiologists, and other CNU registries

## HOW & WHEN: WE'RE GETTING THERE! & NEXT STEPS

## **Design Recap- Accomplishments to Date:**

- ✓ Aligned on Vision, Mission and Governance
- ✓ Developed and refined global aims and theory/approach for improvement
- ✓ Obtained startup funding
- ✓ Developed and refined outcome and process measures
- Established data workgroup with reps to synthesize efforts from all 3 workgroups
- Prioritized/defined data elements for registry forms
- ✓ Drafted forms for workgroups to review
- ✓ Drafted *Central* IRB protocol

## Where We Are Headed

	Apr – Jun 19	Jun – Sep 19	Oct – Dec 19
Meetings	<ul> <li>NPC-QIC Virtual Learning Session (5/3, 5/4)</li> </ul>		NPC-QIC Learning Session (11/2, 11/3)
Data Elements and Registry	<ul> <li>Workgroups Finalize DRAFTs of Data Forms</li> </ul>	<ul> <li>Pilot Care Centers &amp; families test paper forms</li> <li>Compile feedback from Centers &amp; modify forms</li> <li>Vendor Selection Process</li> </ul>	Contract with vendor to begin registry build
IRB Protocol/Legal	➢ Refine IRB Draft	<ul> <li>Update IRB Protocol with Vendor when selected</li> <li>Draft Data Use Agreement or BAA</li> </ul>	Initiate DUA/BAA/IRB approval at FON Participating Care Centers
Design Workgroups	Operational definition for ou		



## FONTAN OUTCOMES NETWORK

Launch 2020!

Fontan Outcomes Network: Optimizing Outcomes

### > Envision the Future:

- ✓ Have data on over 1000 Fontan pts in 2-3 years
- Beginning to reliably track outcomes locally & nationally
- ✓ Can start to understand the individual trajectory
- Building foundation for data driven care strategies and clinical trials
- Evidence-informed advocacy for mental health & school services

## Fontan Outcomes Network: A Paradigm Shift in Single V Lifelong Care

### Thrive not just survive

## Optimize functional outcomes Anticipatory, longitudinal care for early identification and treatment of morbidity

Multi-center, collaborative research, QI, and advocacy


## How You Can Engage with this Work

### >Organize teams/Engage stakeholders:

- Consider clinicians, patients and parents who would be a part of the FON team at your center
- Share with stakeholders that FON is coming soon (patients & parents, clinician colleagues, Heart Center leadership)

Receive periodic FON email updates- email info@npcqic.org to be included

Encourage teen/young adult patients to participate in patient run Fontan session in November (Alicia Wilmoth, Tom Glenn, Meg Roswick Didier)



<u>info@npcqic.org</u> gewright@stanford.edu



NATIONAL PEDIATRIC CARDIC

Quality Improvement Collaborative